About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, ...

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content, and high-sensitivity ...

Intech Investment Management LLC boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 114.8% in the fourth quarter, according to its most recent filing with ...

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in ...

Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign ...

Cytek Biosciences shares jumped 6.1% to $6.78 on Monday. Here are some other big stocks recording gains in today's session. Akso Health Group AHG shares jumped 61.5% to $1.8498.

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 150% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported ...

FREMONT, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has received EN ISO 13485:2016 ...

Cytek Biosciences pioneers in cell analysis with its Full Spectrum Profiling technology. Click her to find out why CTKB stock is rated as a hold.